A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-b peptide of 40-42 amino acid residues 1 . Prefibrillar, soluble oligomers of amyloid-b have been recognized to be early and key intermediates in Alzheimer's-diseaserelated synaptic dysfunction [2] [3] [4] [5] [6] [7] [8] [9] . At nanomolar concentrations, soluble amyloid-b oligomers block hippocampal long-term potentiation 7 , cause dendritic spine retraction from pyramidal cells 5, 8 and impair rodent spatial memory 2 . Soluble amyloid-b oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain 2, 4, 7, 9 . Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-b oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease.
Here we identify the cellular prion protein (PrP C ) as an amyloid-boligomer receptor by expression cloning. Amyloid-b oligomers bind with nanomolar affinity to PrP C , but the interaction does not require the infectious PrP Sc conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-b oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-b-oligomer binding to PrP C and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-b. Thus, PrP C is a mediator of amyloid-b-oligomer-induced synaptic dysfunction, and PrP C -specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
To characterize amyloid-b-oligomer-binding sites, we synthesized amyloid-b(1-42) peptide conjugated to biotin through the a amino group (biotin-Ab42), and then denatured the peptide and allowed oligomers to form as described for amyloid-b-derived diffusible ligands 4 . Consistent with findings for untagged Ab42 oligomers 5 , biotin-Ab42-oligomer preparations contain spherical particles of 5-6 nm in diameter visible by negative staining with transmission electron microscopy, with rare protofibrils and no larger fibrils (Fig. 1a ). Approximately 50% of the peptide migrates by size-exclusion chromatography (SEC) as a distinct assembly with a size of approximately 500 kDa corresponding to 50-100 amyloid-b monomers (Fig. 1b) . Low-molecular-weight forms of Ab42 in either oligomeric or fresh preparations migrate by SEC as monomers ( Fig. 1b) , demonstrating that the trimers or tetramers observed by SDS-polyacrylamide gel electrophoresis ( Supplementary Fig. 1 ) are not present under native conditions 10 . Ab42 oligomer binds to hippocampal neurons, whereas freshly prepared biotin-Ab42 does not ( Fig. 1c and Supplementary  Fig. 2 ). Biotin-Ab42-oligomer binding is enriched in MAP2 (also known as MTAP2)-positive dendrites, with lower levels in bIII-tubulin (TUBB3)-positive axons, and very low levels in astroglial cells ( Supplementary Fig. 3a , c, data not shown and ref. 6 ). The Ab42oligomer binding is most concentrated at post-synaptic densities marked by immunoreactive PSD-95 (also known as DLG4; Supplementary Fig. 3b ). Binding to neurons is saturable, with an apparent dissociation constant (K d ) of 50-100 nM monomer equivalent ( Fig. 1d ). The K d of the relevant Ab42 assembly must be much less than 100 nM because minimal binding is detected with freshly prepared Ab42. If the Ab42 species responsible for binding contains 100 monomers and represents 50% of all biotin-Ab42 in the preparation, the corrected affinity would be ,0.4 nM. Although this formulation of Ab42 oligomer is not chromatographically identical to the Ab42 oligomer from brain 2,3,9 , it affords detection of high-affinity binding sites likely to share pathological actions with sites for other Ab42-oligomer preparations 5, 6, 11 .
A key requirement for expression cloning of Ab42-oligomer-binding sites is the existence of a cell line with low background binding. COS-7 cells exhibit ,5% of the biotin-Ab42-oligomer binding level in hippocampal neurons. We expressed complementary DNAs from an adult mouse brain library in COS-7 cells and screened for biotin-Ab42oligomer binding. From 225,000 clones, 2 independent positive clones were isolated and both were found to encode full-length mouse PrP (Fig. 1e ). Ab42 oligomers bind to cells expressing the PrP C conformation; interaction is not dependent on the PrP Sc conformation required for infectious prion disease 12 . PrP C is known to interact with copper ion but this does not alter Ab42-oligomer binding ( Supplementary Fig. 4 ). Like hippocampal neurons, PrP C -expressing COS-7 cells have much lower affinity for freshly prepared low-molecular-weight biotin-Ab42 ( Fig. 1e and Table 1 ). The apparent dissociation constant for biotin-Ab42-oligomer binding to PrP C -expressing COS-7 cells is indistinguishable from that for biotin-Ab42-oligomer binding to hippocampal neurons ( Fig. 1f , g and Table 1 ). The selectivity of PrP for binding Ab42 oligomer versus fresh Ab42 is reflected in the ratio of K d values and must be greater than 20 (.2,000 nM/92 nM) based on the total peptide monomer concentration in the Ab42-oligomer preparation (Table 1) , or as great as 5,000 (.2,000 nM/0.4 nM) based on the molar concentration of Ab42 oligomer estimated by SEC/light scattering (LS) ( Fig. 1b) .
To explore any contribution of the biotin tag to PrP affinity, we prepared untagged Ab42 oligomer and examined binding to PrP Cexpressing cells with an anti-amyloid-b antibody ( Supplementary  Fig. 5 ). Untagged Ab42 binding is localized to PrP C -expressing cells. Thus, binding is mediated by the amyloid-b amino acid residues. The simplest model for PrP C expression inducing Ab42-oligomer binding is a direct interaction between the two polypeptides. To verify this, we examined the interaction of purified PrP-Fc with Ab42 (Supplementary Fig. 6 ). A control Fc protein, immobilized on a resin, retained neither freshly prepared nor oligomeric preparations of Ab42. In contrast, PrP-Fc protein retained Ab42 peptide through a direct physical interaction. The pre-incubated oligomeric form of Ab42 was retained to a 2.5-fold greater degree than the freshly prepared peptide. The preference of PrP for amyloid-b oligomer versus fresh Ab42 is less complete here than in the cellular assays, perhaps owing to the use of concentrated solid-phase purified reagents and higher concentrations.
Although the PrP cDNA is the only clone to support oligomeric Ab42 binding isolated from the brain cDNA library, we considered whether other amyloid-b-binding sites might exist. First, we examined two clones sharing sequence similarity with PrP-doppel (also known as PRND) and SPRN-but neither showed affinity for oligomeric Ab42 (Table 1 and Supplementary Fig. 7 ). Second, we screened a pre-existing collection of 352 cDNAs encoding transmembrane proteins one by one. In this format, weaker affinity interactions are detectable than in the initial pooled brain library screen. Amyloid-b precursor-like protein 1 (APLP1) and transmembrane protein 30B (TMEM30B) were isolated through this focused screen and demonstrate K d values for oligomeric Ab42 of 660 nM and 720 nM, respectively ( Table 1 and Supplementary Fig. 7 ). These lower affinity binding proteins exhibit limited specificity for oligomeric Ab42, as compared to fresh Ab42. APLP1 shares similarity with amyloid-b precursor protein (APP) and with APLP2, but neither of these proteins binds Ab42 (Table 1) . TMEM30B is similar to TMEM30A, which is expressed at high levels in the brain. TMEM30A supports Ab42 binding with an affinity similar to TMEM30B and shows no preference for oligomeric species (Table 1) . The receptor for advanced glycation end products (RAGE) and the a7 nicotinic acetylcholine receptor (nAChRa7, also known as CHRNA7) have been reported to bind amyloid-b 13, 14 . In this heterologous COS-7 cell binding assay, expression of RAGE yielded less Ab42-oligomerbinding signal than did PrP, APLP1 or TMEM30B, and we failed to detect binding to nAChRa7 ( Supplementary Fig. 7 ). Thus, although several proteins exhibit Ab42 binding, only PrP has high affinity and high selectivity for the oligomeric peptide.
Binding of Ab42 oligomer to neurons depends on the developmental stage, with minimal binding to neurons immediately after dissociation from E18 hippocampus. Binding of Ab42 oligomer to neurons does not become robust until 15-20 days have elapsed in vitro ( Fig. 2a ). The immunoblot level of PrP C expression closely matches this developmental pattern ( Fig. 2b ). Immunocytochemically, PrP C expression is largely restricted to MAP2-positive dendrites of differentiated neurons ( Supplementary Fig. 3d and Fig. 2c ). Furthermore, localization of PrP immunoreactivity and Ab42-oligomer binding overlap extensively ( Fig. 2c ). If PrP C (encoded by Prnp) were the only cellular binding site for Ab42 oligomers, then no binding would be detected in cultures from Prnp 2/2 mice at 20 days in vitro (DIV). Because we observe 50% reduction of punctate Ab42-oligomer binding in such cultures ( Fig. 2d, e ), PrP C cannot be the only cell-surface molecule binding Ab42 oligomers. Multiple alternative sites, including APLP1, TMEM30A, TMEM30B, RAGE and unidentified proteins, may explain Ab42 binding to Prnp 2/2 neurons. Different domains of PrP C have been associated with various activities. The amino-terminal octapeptide repeat domain (amino acids 60-95) contributes to extracellular copper ion binding 15, 16 . The unstructured central domain (amino acids 95-134) includes a charge cluster (amino acids 95-110) and a segment with hydrophobic character (amino acids 112-134). This central domain has been implicated in masking a neurodegenerative activity of PrP C (refs 17 and 18). The carboxy-terminal domain is globular (amino acids 134-231) 19 and the protein is glycosyl phosphatidylinositol (GPI)-anchored to the plasma membrane. We mapped Ab42-oligomer binding using PrP deletion mutants ( Fig. 3 ). Each mutant protein was expressed at the COS-7 surface by live anti-PrP immunostaining ( Fig. 3a and Supplementary Fig. 8 ). Deletion of the octapeptide repeat domain and the central domain (D32-121) abrogates binding, indicating that the globular domain alone cannot mediate binding. The hydrophobic 105-125 region is not a major determinant, because D105-125 protein binds Ab42 oligomers indistinguishably from full-length PrP C , and because the D32-106 variant behaves like the D32-121 variant, having no Ab42oligomer affinity. To distinguish whether the 95-110 charge cluster or the octapeptide repeat domain is crucial for Ab42 binding, a mutant lacking the 52-91 segment was expressed. The D52-91 mutant exhibits significant Ab42 binding, implicating the 95-110 region as a principal site for Ab42-oligomer binding. Consistent with this hypothesis, deletion of 11 amino acids in the D95-105 variant reduced binding by 80%, and there was no further reduction in the D70-105 variant.
As an alternative method to localize Ab42 binding within PrP C , we used anti-PrP antibodies ( Fig. 3b-d ). Of the six antibodies initially tested, only one (6D11) blocked the binding of Ab42 assemblies to PrP C , and did so with a half-maximal inhibitory concentration of 1 nM (Fig. 3b-d and Supplementary Figs 8-10 ). The 6D11 blockade is epitope-specific because the 7D9 antibody binds avidly to a different epitope but fails to block Ab42 binding ( Fig. 3a-d and Supplementary  Figs 8 and 9 ). The epitope for 6D11 corresponds to amino acids 93-109 of mouse PrP C , matching the conclusion that the 95-105 amino LETTERS acid region is a primary determinant for binding. To confirm this hypothesis, we examined the effect of an additional antibody (8G8) with an overlapping epitope, amino acids 95-110. The 8G8 antibody blocked the Ab42-PrP C interaction, although with a lesser potency than 6D11. The effect of 6D11 was not caused by internalization of PrP C , because similar cell-surface levels of PrP C were detectable after 6D11 pre-incubation ( Supplementary Fig. 11 ). The 6D11 antibody is highly specific for PrP C , as no immunoreactivity was observed in Prnp null brain sections nor was there any reactivity to Ab42 ( Supplementary Fig. 12 and not shown). We conclude that the 95-105 segment of PrP C contributes to Ab42-oligomer binding in a 6D11-sensitive manner.
Although these data demonstrate that PrP C is a high-affinity binding site for Ab42 oligomers, they do not assess its role in the pathological actions of Ab42. It has been noted that soluble Ab42 oligomers suppress long-term potentiation (LTP) of the Schaffer collateral pathway between hippocampal CA3 and CA1 pyramidal cells 7, 11 . Therefore, we compared the effects of soluble Ab42 oligomers on LTP from slices of wild-type versus Prnp 2/2 mice 20,21 . As reported previously, soluble Ab42 oligomers (500 nM total peptide, estimated 2 nM Ab42 oligomer) reduce LTP in hippocampal slices from wildtype mice (Fig. 4a, d) . The slope of the excitatory postsynaptic potential (EPSP) after theta burst stimulation is augmented by 80% in control slices, but only by 20% in slices pre-incubated with Ab42oligomer preparations. In slices from 2-6-month-old PrP null mice without Ab42 treatment, Schaffer collateral LTP is indistinguishable from baseline levels of wild-type mice (Fig. 4b) , as described previously 22, 23 . Notably, there is no inhibition of LTP by Ab42 oligomers in the Prnp 2/2 slices ( Fig. 4b-d ).
The lack of Ab42 sensitivity for LTP in Prnp 2/2 slices indicates that PrP C acts as a receptor for Ab42 oligomers mediating inhibition of LTP in wild-type slices. Alternatively, chronic loss of PrP C may lead to developmental and/or compensatory effects that account indirectly for Ab42 oligomer ineffectiveness. To separate these possibilities, we pretreated wild-type slices with the 6D11 anti-PrP antibody (100 nM for 20 min), which was shown to block Ab42 binding acutely (Fig. 3) . Pretreatment with control immunoglobulin G did not reduce the suppression of LTP by Ab42 oligomer (Fig. 4d) . In contrast, the 6D11-pretreated wild-type slices were protected from LTP suppression by the later addition of Ab42-oligomer preparations (Fig. 4d ). Thus, we conclude that PrP C exerts a receptor action acutely to mediate Ab42-oligomer inhibition of synaptic plasticity in the hippocampal slice.
The principal finding of this study is that PrP C functions as a receptor to mediate the deleterious effects of the Ab42 oligomer. This hypothesis is supported by our isolation of PrP C as an Ab42-oligomerbinding site in an unbiased genome-wide screen, by the match between PrP C expression and the properties of Ab42-oligomer-binding sites, and by the localization of amyloid-b binding to a neurodegenerationassociated domain of PrP C . Although PrP C is not the sole binding site for amyloid-b oligomers on hippocampal neurons, it is essential for Ab42-oligomer inhibition of hippocampal LTP. Several publications indirectly support coupling of Ab42 oligomers and PrP C . For example, Ab42 (30 nM) binding to hippocampal neurons after culture for the indicated time. Neuronal cell density is similar in the three panels. Scale bar, 100 mm. b, Total protein (20 mg) from hippocampal cultures, from whole brain of the indicated genotype or from HEK293T cells transfected with a PrP expression vector was analysed by immunoblot with anti-PrP antibody (8H4), with anti-bIII-tubulin antibody or with anti-GAPDH antibody. Samples for the middle panel were pretreated with endoglycosidase (PNGase F) before gel electrophoresis through a 4-20% polyacrylamide gel in Tris-glycine-SDS. Molecular weight standards are shown at the left in kDa. c, Hippocampal neurons from E18 mice after 21 DIV were incubated with biotinylated Ab42 oligomer (130 nM monomer equivalent) for 1 h at 37 uC and then fixed. Bound amyloid-b was detected with fluorescent avidin (green), and PrP C with anti-PrP immunocytochemistry (red). Scale bar, 100 mm. d, Cultures were prepared from wild-type (WT) or Prnp 2/2 mice, and then binding of Ab42-oligomer (130 nM monomer equivalent) was detected as in c. Scale bar, 10 mm. e, Binding of 100 nM Ab42 oligomers to puncta in hippocampal cultures as shown in d. Data from n 5 6 pairs of cultures from wild-type and Prnp 2/2 embryos. Mean and s.e.m.; *P , 0.05, two-tailed t-test. a polymorphism in Prnp gene is associated with Alzheimer's disease in certain populations 24 and with long-term memory formation in the general population 25 . Amongst several proteins found in PrP C immunoprecipitates are APP and the related proteins APLP1 and APLP2 (refs 26 and 27) .
Glutamate receptors are central to LTP and their modulation has been implicated in deleterious synaptic amyloid-b action 5, 8, 28, 29 .
Recently, PrP C has been shown to interact with N-methyl-D-aspartate receptor subunit 2D (NR2D, also known as GRIN2D), and to modulate its function 30 . We assessed whether Ab42 interaction might regulate glutamate receptors directly through PrP C . When expressed in a heterologous Xenopus laevis oocyte system, GluR1-4 (GRIA1-4) receptors and NR2B (GRIN2B)-and NR2D-containing receptors are insensitive to Ab42 oligomers, with or without PrP C co-expression ( Supplementary Figs 14 and 15 ). This is consistent with previous observations that amyloid-b drives glutamate receptor redistribution in neurons together with morphologic changes in dendrites 5, 8, 9 . Thus, the Ab42-oligomer interaction with PrP C is likely to initiate a signalling cascade that is not operative in oocytes, but one that is capable of modifying synaptic morphology and function in the brain. The mechanism by which Ab42-oligomer binding to PrP C participates in Alzheimer's disease appears unrelated to the infectious PrP Sc conformation of PrP. In this regard, the neurodegeneration reported in transgenic mice expressing truncated forms of PrP C may be more relevant 17, 18 . A putative PrP C -associated transmembrane co-receptor is likely to have a central role in Alzheimer's-disease-mediated neurodegeneration. PrP C -specific reagents will provide molecular tools to dissect the cellular basis for Ab42-oligomer-induced changes in synaptic function. The interaction between amyloid-b and PrP C provides a new site for the development of therapeutics designed to relieve Alzheimer's disease symptoms.
METHODS SUMMARY
Mouse strains. Prnp 2/2 mice (Edinburgh strain) 21 on an inbred C57Bl6 background were obtained from B. Chesebro and Prnp 2/2 mice (Zurich I) 20 on a mixed strain background were obtained from the European Mutant Mouse Archive.
Ab42 preparation and cellular binding. Ab42 oligomer preparations were generated from synthetic peptide 4 . For binding assays, COS-7 cells were transiently transfected with cDNA expression plasmids or isolated hippocampal neurons were cultured from E18 embryos. Bound biotin-Ab42 was detected using avidin conjugates.
Electrophysiology. Hippocampal slices (400 mm) from C57Bl6J or Prnp 2/2 mice were bathed in oxygenated artificial cerebrospinal fluid. The Schaffer collateral pathway was stimulated at 0.033 Hz at levels that evoked less than 50% of maximal field EPSPs. Evoked CA1 field potentials were recorded and the slope of the EPSP determined (Clampfit, Molecular Devices). Ab42 or antibodies were bath-applied for 20-40 min before inducing LTP with ten 100-Hz trains at five pulses delivered at 5 Hz.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Ab42 preparations. Oligomerized human Ab42 was prepared as described 5, 6 with minor modifications. Ab42 peptide or Ab42 with a biotin moiety attached by 6-carbon linker to the N terminus (both synthesized at Yale in the Keck Biotechnology Resource Laboratory, ,99% pure) were dissolved in 1,1,1,3,3,3hexafluoro-2-propanol, dried and stored at 280 uC. The dried peptide was reconstituted in anhydrous DMSO at 100 mM, and then diluted in F12 media (Invitrogen) to a final concentration of 100 mM. After 16 h incubation at 22 uC, the preparation was centrifuged at 21,000g for 15 min, and the supernatant was collected for experiments. Mouse strains. Prnp 2/2 mice (Edinburgh strain) 21 on an inbred C57Bl6 background (greater than ten backcrosses) were obtained from B. Chesebro, and Prnp 2/2 mice (Zurich I) 20 on a mixed strain background were obtained from the European Mutant Mouse Archive. All electrophysiological strain comparisons were completed by experimentalists unaware of the mouse genotype. Biophysical characterization of Ab42 oligomers. For electron microscopic analysis, oligomerized human Ab42 was prepared as above. Fresh Ab42 was prepared by dissolving dried peptide similarly into DMSO and then into F12 media immediately before use. Ab42 fibrils were prepared by dissolving dried peptide in DMSO and then diluting into PBS followed by 24 h incubation at 37 uC with 100 r.p.m. mixing. All Ab42 preparations were stained with 2% phosphotungstic acid (pH 7.0) for 2 min and imaged with Tecnai 12 Biotwin transmission electron microscope at 160,000-fold magnification. For analysis of the molecular weight of oligomerized human Ab42, SEC combined with light scattering analysis was used. The SEC data were collected using a sequential connection of Superdex 200, Superdex 75, and Superdex peptide, 10/30, HR SEC columns (GE Healthcare), connected to high-performance liquid chromatography system, Alliance 2965 (Waters Corp.), equipped with an autosampler. The elution from SEC was monitored by a photodiode array (PDA) UV/VIS detector (996 PDA, Waters Corp.), differential refractometer (OPTI-rEx, Wyatt Corp.) and static, multiangle laser LS detector (DAWN-EOS, Wyatt Corp.). The SEC-UV/LS/RI system was equilibrated in F12 media at the flow rate of 0.5 ml min 21 . Two software packages were used for data collection and analysis: the Millennium software (Waters Corp.) controlled the high-performance liquid chromatography operation and data collection from the multi-wavelength UV/ VIS detector, whereas the ASTRA software (Wyatt Corp.) collected data from the light scattering detector, and recorded the UV trace at 220 nm sent from the PDA detector. The weight average molecular masses were determined across the entire elution profile in the intervals of 1 s from the static LS measurement using the ASTRA software as described previously 31 . Expression cloning and COS-7 cell binding assays. We screened an arrayed adult mouse brain cDNA library (Origene) of 225,000 clones by transfecting COS-7 cells with pools of 5,000 clones, and visually inspecting for those rare cells transfected with a cDNA conferring Ab42-oligomer binding. Two days after transfection, the cells were incubated with Ab42 oligomers (1 mM total Ab42 monomer concentration) in F12 media at 22 uC for 2 h. Next, unbound Ab42 was removed by extensive washing with F12 media. The cells were fixed with 3.7% formaldehyde, washed three times with PBS, incubated in 65 uC for 2 h, blocked for 20 min with 3% goat serum and 0.1% Triton X-100 in PBS, and incubated for 16 h with alkaline-phosphatase-conjugated steptavidin in PBS supplemented with 1.5% goat serum and 0.05% Triton X-100. Finally, bound alkaline phosphatase was visualized by 5-bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium reaction. The initial screen was followed by sequential fractionation of sub-pools. This process led to identification of two independent cDNA clones mediating high-affinity binding of Ab42 oligomers to transfected COS-7 cells. Sequencing of the inserts revealed that both clones encode fulllength PrP C . We also performed a directed experiment to identify putative low-affinity Ab42-oligomer receptor(s): a library consisting of 352 individual preparations of cDNAs encoding transmembrane proteins (GFC-transfection array panel, Origene) was transfected into COS-7 cells, and binding was detected as above. We also tested similarly several candidate receptors; the cDNA plasmids were obtained from Origene or Open Biosystems. Quantification of bound Ab42 to PrP-transfected COS-7 cells was performed with ImageJ similarly to that described previously [32] [33] [34] [35] . For analysis of oligomeric Ab42 binding to mouse PrP deletion constructs, the indicated constructs were transfected into COS-7 cells. PrP D105-125 expression construct was provided by D. Harris 18 . PrP D32-121, PrP D32-106 and PrP D52-91 were provided by E. Flechsig and C. Weismann 36 . To obtain PrP D70-105 and PrP D95-105 expression constructs, nucleotides encoding mouse PrP amino acids 106-254 and the C-terminal stop codon were PCR-amplified with primers containing EcoRI and XhoI sites, and the fragment was cloned into EcoRI and XhoI sites of pcDNA3.1/mycHis A (Invitrogen). Next, nucleotides encoding mouse PrP amino acids 1-69 or 1-94 were PCR-amplified with primers containing HindIII and EcoRI sites, and the fragments were cloned into HindIII and EcoRI sites of the above-mentioned PrP 106-254 pcDNA3.1/mycHis A construct.
For double-immunostaining of PrP C expressed on COS-7 cells and bound non-biotinylated Ab42, the rabbit anti-Ab42 antibody (Cell Signaling Technology) was used in combination with 7D9 PrP mouse monoclonal antibody (Covance). Alexa Fluor 488 goat anti-rabbit and 568 goat anti-mouse secondary antibodies (Invitrogen) were used. No specific signal was obtained with amyloid-b antibody without the addition of amyloid-b on PrP-expressing cells, or when incubating amyloid-b with non-transfected control cells. Antibody blocking experiments. The following PrP antibodies were used: S8B4 (mouse monoclonal; epitope mapped to amino acids 32-69 of PrP ( Supplementary  Fig. 8 ), 8B4 clone from Santa Cruz Biotechnology), M-20 (affinity-purified goat polyclonal; raised against peptide located in the C-terminal half of mouse PrP ( Supplementary Fig. 8 ), Santa Cruz Biotechnology), 7D9 (mouse monoclonal; according to manufacturer epitope between amino acids 105 and 125 of mouse PrP, Covance/Signet), 6D11 (mouse monoclonal; according to manufacturer epitope between amino acids 93 and 109, Covance/Signet), A8B4 (mouse monoclonal; according to manufacturer epitope between amino acids 37 and 44 of mouse PrP, 8B4 clone from Alicon GH), MAB5424 (mouse monoclonal; epitope mapped to amino acids 105-125 ( Supplementary Fig. 8 ), Chemicon), and 8G8 (mouse monoclonal; epitope between amino acids 95 and 110, Cayman Chemical/SPIbio). In live-cell staining application, all antibodies robustly recognized PrP expressed on COS-7 cells ( Supplementary Fig. 8 ). To detect the blockade of Ab42-PrP interaction, COS-7 cells transfected 2 days earlier with PrP expression vector were preincubated with the indicated concentrations of antibodies in F12 media at 22 uC for 1 h. Next, biotin-Ab42 oligomers were added to a final concentration of 250 nM for 2 h. Finally, bound Ab42 was visualized as described previously. PrP-Fc pull-down experiments. HEK293T cells were transiently transfected with expression vector encoding mouse PrP (codon 1-230, devoid of GPI-anchor modification sequence) fused to the Fc region of human IgG1 (ref. 37) . Secreted PrP-Fc fusion was bound on protein G Sepharose CL-4B (GE Healthcare), and contaminants were removed by washes with increasing concentrations of buffered NaCl solution. Control human IgG Fc fragment (Bethyl Laboratories) was similarly coupled to protein G Sepharose. Aged oligomerized or fresh Ab42 was incubated with Fc proteins for 2 h at 4 uC, washed extensively with F12, and the bound material was analysed by western blotting with 6E10 amyloid-b antibody. For quantification of bound material, infrared fluorescence secondary antibodies were used in combination with Odyssey infrared imaging system (LI-COR Biosciences); the signal across the whole lane was quantified with Odyssey software. The reported result is average 6 s.e.m. from four experiments. Neuron cultures and neuronal binding assays. Rat and mouse E18 hippocampal neurons were cultured in Neurobasal-A media supplemented with B-27, 0.5 mM L-glutamine, penicillin and streptomycin (all from Invitrogen) on tissue culture plates or on Lab-Tek II-CC2 chamber slides (Nunc) coated with poly-Llysine and laminin. For the analysis of PrP expression, neurons were lysed with RIPA buffer after the indicated time in vitro. Also wild-type and Prnp 2/2 mouse brain lysates and PrP-expressing HEK293T cell lysates were prepared. The lysates were analysed by western blotting with 8H4 anti-PrP antibody (Alicon AG), anti-bIII-tubulin antibody (Covance), and anti-GAPDH antibody (Sigma). To remove carbohydrate-moieties from PrP, some samples were treated with PNGase F (New England Biolabs). For immunocytochemistry, the following antibodies were used: anti-PrP (mouse monoclonal, 8H4 clone, Alicon AG), anti-MAP2 (chicken polyclonal, Chemicon) and anti-PSD95 (rabbit polyclonal, Zymed/Invitrogen). For rat neurons, binding of Ab42 was determined as in COS-7 cell binding assays. To determine bound biotin Ab42 oligomers in wild-type and Prnp 2/2 cultures, an Ab42-oligomer concentration equivalent to 80 nM of monomer Ab42 (,0.3 nM oligomer) was used. The bound biotin-Ab42-oligomers were visualized with NeutrAvidin Oregon Green 488 conjugate (Invitrogen) and dendrites with anti-MAP2 antibody (chicken polyclonal, Chemicon). Fluorescent images were captured at 363 with fixed illumination and exposures, and then processed using NIH Image. Integrated signal intensity for bound Ab42 oligomer in puncta of less than 50 mm 2 was measured after thresholding and background subtraction across both wild-type and Prnp 2/2 images. The integrated punctate amyloid-b signal was divided be the area of MAP-2-positive dendrite in each image, to generate units of Ab42 oligomer binding to puncta per dendritic area. Electrophysiology. Adult (2-6 months of age) C57BL/6J or Prnp 2/2 mice were decapitated, and their brains rapidly removed and immersed in ice-cold artificial cerebrospinal fluid (aCSF). The composition of the aCSF was as follows: 119 mM NaCl, 2.5 mM KCl, 1.3 mM MgCl 2 , 2.4 mM CaCl 2-, 26.2 mM NaHCO 3 , 11 mM D-glucose, 1.25 mM NaH 2 PO 4 . Coronal sections (400 mm) were prepared on a Vibratome 1000 Plus, using stainless steel razor blades. Slices were allowed to recover for at least 2 h in a submerged incubation chamber (BSC-PC, Warner
